Drugs by condition
Drugs approved for sarcoma
Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
9
Still marketed, NDA or BLA
Drug classes
4
Novel drugs
4
New molecular entities and new biologics
In development
28
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for sarcoma.
- Oxderys (Doxorubicin Hydrochloride) · Avyxa Holdings Nov 9, 2026
- Tecentriq Hybreza (Atezolizumab and Hyaluronidase-Tqjs) · Genentech INC Sep 12, 2024
- Tecentriq (Atezolizumab) · Genentech INC NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanMay 18, 2016
- Pomalyst (Pomalidomide) · Bristol NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanFeb 8, 2013
- Votrient (Pazopanib Hydrochloride) · Novartis NovelOrphanOct 19, 2009
All approved drugs for sarcoma, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 38 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Programmed Death Receptor-1 Blocking Antibody (2)
- Tecentriq Atezolizumab · Genentech INC · 2016
- Tecentriq Hybreza Atezolizumab and Hyaluronidase-Tqjs · Genentech INC · 2024
Thalidomide Analog (1)
- Pomalyst Pomalidomide · Bristol · 2013
Retinoid (1)
- Panretin Alitretinoin · Advanz Pharma · 1999
Class not listed in FDA's data (5)
- Votrient Pazopanib Hydrochloride · Novartis · 2009
- Oxderys Doxorubicin Hydrochloride · Avyxa Holdings · 2026
- Doxil (Liposomal) Doxorubicin Hydrochloride · Baxter Hlthcare Corp · 1995
- Nebupent Pentamidine Isethionate · Fresenius Kabi USA · 1989
- Doxorubicin Hydrochloride Doxorubicin Hydrochloride · Pfizer · 1987
Drugs in development for sarcoma
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- Anlotinib hydrochlorideAL3818, CatequentenibPhase 312 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Alveolar Soft Part Sarcoma, Metastatic Colorectal Cancer, Endometrial Neoplasms
- L19TNFL19IL2, OnfekafuspPhase 310 trials
Philogen S.p.A. · Glioblastoma, Locally Advanced Basal Cell Carcinoma, Melanoma Stage III
- MK-2140Zilovertamab Vedotin, VLS-101Phase 39 trials
Merck & Co. · Diffuse Large B-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, B-cell Acute Lymphoblastic Leukemia
- AL8326Phase 34 trials
Advenchen Pharmaceuticals, LLC. · Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms
- ChiauranibCS2164Phase 33 trials
Chipscreen Biosciences, Ltd. · Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Soft Tissue Sarcoma
- KC1036Phase 33 trials
Beijing Konruns Pharmaceutical Co., Ltd. · Ewing Sarcoma, Esophageal Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma (ESCC)
- 1.0% IP-001IP-001Phase 32 trials
Immunophotonics, Inc. · Colorectal Cancer (CRC), Colon Cancer Liver Metastases, Rectal Cancer
- INT230-6Phase 31 trial
Intensity Therapeutics, Inc. · Sarcoma,Soft Tissue
- TBI-1301Phase 31 trial
Takara Bio Inc. · Synovial Sarcomas
- BenmelstobartPhase 24 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Alveolar Soft Part Sarcoma, Non-Small Cell Lung Cancer, Gastroesophageal Adenocarcinoma
- T3011Phase 24 trials
Shanghai Pharmaceuticals Holding Co., Ltd · Advanced Solid Tumors, Nonmuscle-invasive Bladder Cancer, Solid Tumor
- ADCAntibody-drug conjugate, ADCE-D01Phase 23 trials
MBrace Therapeutics · Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer, Colo-rectal Cancer
- Recombinant Human IL1215-PDL1B Oncolytic HSV-1, VG161Phase 23 trials
CNBG-Virogin Biotech (Shanghai) Ltd. · Advanced Malignant Solid Tumor, Sarcoma, Advanced Intrahepatic Cholangiocarcinoma
- AL58805Phase 22 trials
Advenchen Pharmaceuticals, LLC. · Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms
- CAB-AXL-ADCBA3011Phase 22 trials
BioAtla, Inc. · Non-Small-Cell Lung Cancer, Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
- Checkpoint InhibitorPhase 22 trials
EpicentRx, Inc. · Solid Tumor, Adult, Cancer, Neoplasms
- GI-102Phase 22 trials
GI Innovation, Inc. · Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS)
- HH2853Phase 22 trials
Haihe Biopharma Co., Ltd. · Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL), FL Lymphoma, Epithelioid Sarcoma
- Tigilanol TiglateEBC-46Phase 22 trials
QBiotics Group Limited · Soft Tissue Sarcoma, Head and Neck Cancer
1 discontinued brand-name drugs whose label still names it
- Tazverik Tazemetostat Hydrobromide
More on sarcoma: recruiting trials · published research
Related in oncology: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Prostate cancer · Colorectal cancer · Melanoma · Ovarian cancer · Pancreatic cancer · Bladder and urothelial cancer · Kidney cancer (renal cell carcinoma)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.